Agree Eagle0 except if/once NNZ2591 is commercialised the patient starts and persistence will dwarf trofinetide due to 2591's incomparable safety and tolerability profile. There appears very little if any downside to taking it so IMO patients will just stay on it given the improvements over time seen with Daybue. I believe you could easily double total penetration for 2591 cf trofinetide which renders the numbers almost absurd.
NEU Price at posting:
$13.38 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)